The emergence and outbreak of emerging infectious diseases is a global challenge to public health. At present, scientists from academia and biopharmaceutical industries around the world are working hard to find ways to prevent and treat coronavirus infections. Creative Biostructure has rapidly integrated related businesses characterized by structural biology and currently provides preclinical development services for recombinant vector vaccines to meet the urgent needs of SARS-CoV-2 vaccine R&D. More info : Recombinant Vaccine Definition

The recombinant subunit vaccine the immune response of the human body by directly injecting the subunit of the pathogen into the body. This method is generally of low immunogenicity and can only induce the humoral immune response of the human body. Therefore, to simultaneously induce the humoral and cellular immune processes of the human body and improve the immunogenicity of vaccines, several technical platforms have been developed to directly produce antigen proteins in the human body. The recombinant virus vector vaccine is one of the important emerging technologies.